Imdevimab(TD-VK565056) is a research-grade recombinant antibody targetingSpike glycoprotein. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
SARS-CoV-2 (2019-nCoV)
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Human
Isotype
IgG1, lambda
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Endotoxin level
Please contact the lab for this information.
Purity
>95% purity as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
REGN-10987, REGN10987, 2415933-40-1
Caption
SEC-HPLC detection for Research Grade Imdevimab. ### Detects Recombinant SARS-CoV-2 Spike protein receptor binding domain (Cat No.:VK565021) in indirect ELISA. | SDS-PAGE for Research Grade Imdevimab.
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询